ARCA biopharma (NASDAQ:ABIO – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a report released on Tuesday.
ARCA biopharma Price Performance
Shares of NASDAQ ABIO traded up $0.07 during mid-day trading on Tuesday, reaching $3.55. 94,737 shares of the company’s stock traded hands, compared to its average volume of 706,128. The stock has a market cap of $51.51 million, a P/E ratio of -8.45 and a beta of 0.90. The business has a 50-day simple moving average of $3.44 and a 200 day simple moving average of $2.58. ARCA biopharma has a 1-year low of $1.56 and a 1-year high of $4.49.
ARCA biopharma (NASDAQ:ABIO – Get Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter.
Insider Buying and Selling
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ARCA biopharma stock. Cable Car Capital LLC bought a new stake in ARCA biopharma, Inc. (NASDAQ:ABIO – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,000,452 shares of the biopharmaceutical company’s stock, valued at approximately $6,801,000. ARCA biopharma comprises approximately 7.6% of Cable Car Capital LLC’s portfolio, making the stock its 4th biggest position. Cable Car Capital LLC owned approximately 27.59% of ARCA biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 56.44% of the company’s stock.
ARCA biopharma Company Profile
ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
Read More
- Five stocks we like better than ARCA biopharma
- The How and Why of Investing in Gold Stocks
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- How to Use Stock Screeners to Find Stocks
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- The 3 Best Fintech Stocks to Buy Now
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.